We are international

New Phase II trial opens with VELCADE as front-line therapy
"Phase II Trial of PS-341 Alone and in Combination with Dexamethasone in Previously Untreated Multiple Myeloma Patients."

This is a Multicenter study of PS-341, either alone or in combination with dexamethasone, in the treatment of newly diagnosed multiple myeloma. Patients must have measurable disease in the form of serum or urine monoclonal immunoglobulin spike or visible disease, such as soft tissue plasmacytoma. Patients will receive PS-341 as a single agent for the first two cycles; in the event of less than a partial response dexamethasone will be added. Following the fourth cycle any patient with less than a complete response (CR) will have dexamethasone added to the treatment cycles.

This is an investigator-initiated trial that is currently enrolling patients at the following sites:

  • Alta Bates Comprehensive Cancer Center; Berkeley, CA. Contact: Jeffrey Wolf, M.D. - 510-204-1591
  • Cedars-Sinai Medical Center, Beverly Hills, CA.
    Contact Brian Durie, MD - 323-966-3572 (Executive Assistant - Jennifer King).
  • Comprehensive Cancer Center of the Desert; Palm Desert, CA.
    Contact: Larry Leichman, M.D. - 760-416-4860
  • St. Vincent's Comprehensive Cancer Center; New York City, NY.
    Contact: Sundar Jagannath, M.D. - 212-604-6068

For further information, please contact the IMF hotline at (800) 452-2873.

 related articles